AstraZeneca Investor Day Presentation Deck
March 2021, 86 slides
  1. AstraZeneca
  2. Related Decks
  3. Investor Day Presentation Decks
meet management | AstraZeneca
forward looking statements | AstraZeneca
agenda | AstraZeneca
chronic diseases are a staggering growing burden to patients and society | AstraZeneca
leading with an unmatched portfolio and growing pipeline | AstraZeneca
strong commercial execution | AstraZeneca
emerging markets footprint across four continents and over countries | AstraZeneca
emerging markets strong growth both in china and other ems ranked | AstraZeneca
unique opportunity to transform kidney care by billion million three thousand thousand partnerships | AstraZeneca
transforming care for patients with severe asthma by aiming for uptake similar to other inflammatory diseases million digital thousand | AstraZeneca
building the team of the future | AstraZeneca
agenda | AstraZeneca
framework has increased productivity | AstraZeneca
productivity in progress made across all | AstraZeneca
focus areas to further improve productivity | AstraZeneca
identifying new targets through enabled big data | AstraZeneca
a broad set of therapeutic platforms to target any biology | AstraZeneca
novel chemistry advances project portfolio five five three | AstraZeneca
cell therapy approaches focused on regeneration ongoing across all therapy areas | AstraZeneca
led small molecule discovery is driving efficacy of small molecule projects are applying approaches | AstraZeneca
predictive science continues to improve our clinical trial performance | AstraZeneca
accelerating clinical efficiency through digital innovation is world first indication seeking registry based controlled outcomes trial | AstraZeneca
overall pipeline innovation to fuel sustainable growth | AstraZeneca
agenda | AstraZeneca
covid treatment and prevention approaches advancing vaccine antibody other options | AstraZeneca
vaccine development typically takes a decade or longer an unprecedented acceleration i | AstraZeneca
covid vaccine shown to be safe and effective in clinical trials and real world data | AstraZeneca
clinical priorities | AstraZeneca
long acting antibody combination covid unmet needs persist even during a successful vaccine | AstraZeneca
agenda | AstraZeneca
questions answers | AstraZeneca
meet management four a focused virtual breakout sessions | AstraZeneca
| AstraZeneca
new emerging pipeline | AstraZeneca
forward looking statements | AstraZeneca
bold ambitions in four disease areas with medicines million million million million | AstraZeneca
potential for improved efficacy with convenient at home administration | AstraZeneca
small molecule inhibitor targeting blood vessels inflammation and fibrosis | AstraZeneca
novel fixed dose combinations and with opportunity to enhance efficacy | AstraZeneca
dual and receptor agonist promising efficacy in overweight patients with fatty liver | AstraZeneca
full pipeline and news flow upcoming milestones and expanding pipeline | AstraZeneca
questions answers | AstraZeneca
appendix | AstraZeneca
publications | AstraZeneca
publications continued cominged | AstraZeneca
| AstraZeneca
new near term opportunities | AstraZeneca
forward looking statements | AstraZeneca
broad development beyond i | AstraZeneca
new and upcoming milestones billion | AstraZeneca
affects adults silent progressive high mortality disease significantly billion million a loy | AstraZeneca
rapid and sustained potassium control for patients with | AstraZeneca
shifting the treatment paradigm for patients with anaemia from | AstraZeneca
full pipeline and news flow expanding from and to | AstraZeneca
questions answers | AstraZeneca
appendix | AstraZeneca
publications | AstraZeneca
publications continued rend | AstraZeneca
| AstraZeneca
respiratory immunology emerging pipeline break out session | AstraZeneca
forward looking statements | AstraZeneca
targeting diseases with great unmet medical need building on years of respiratory care in immune driven diseases patients irene patients | AstraZeneca
respiratory immunology strategy disease modification and clinical remission | AstraZeneca
targeting a broad acting damage response epithelial me | AstraZeneca
targeting a broad acting damage response epithelial | AstraZeneca
and addressing unmet need in asthma mere | AstraZeneca
fusion protein specific for and potential synergy between blocking and in pain | AstraZeneca
full pipeline and news flow upcoming milestones and expanding pipeline | AstraZeneca
questions answers | AstraZeneca
appendix | AstraZeneca
publications | AstraZeneca
| AstraZeneca
respiratory immunology near term opportunities | AstraZeneca
forward looking statements | AstraZeneca
respiratory diseases under and under treated one | AstraZeneca
and strength in inhaled medicines next generation medicines for mild and moderate disease | AstraZeneca
and asthma leadership greater use of anticipated in severe asthma | AstraZeneca
increasing presence in immunology pursuing leadership starting with lupus | AstraZeneca
first new treatment in years potential first in class with robust efficacy plans include myositis | AstraZeneca
full pipeline and news flow upcoming milestones and key | AstraZeneca
questions answers | AstraZeneca
appendix | AstraZeneca
publications | AstraZeneca
publications continued | AstraZeneca
publications continued | AstraZeneca
| AstraZeneca
See More
AstraZeneca
Investor Day Presentation Decks
Drug Manufacturers—General Decks
Healthcare Decks
Explore Topics
Medicine
Recent decks by AstraZeneca
Results
February 2025
Results
November 2024
Results
November 2024
Investor Event
September 2024
See all presentations by AstraZeneca (31 decks)
Related decks
Absci
Investor Conference
January 2023
uBiome
Start Up
June 2017
Tivic Health Systems
Investor Presentation
October 2022
AbCellera
Results
August 2023
Nuvectis Pharma
Investor Presentation
July 2023
Evotec
Investor Presentation
July 2022
Exscientia
Investor Day
January 2024
MindMed
Investor Presentation
April 2021
Recent decks by AstraZeneca
See all presentations (31 decks)
Results
February 2025
Results
November 2024
Results
November 2024
Investor Event
September 2024
Absci
Investor Conference
January 2023
uBiome
Start Up
June 2017
Tivic Health Systems
Investor Presentation
October 2022
AbCellera
Results
August 2023
Nuvectis Pharma
Investor Presentation
July 2023
Evotec
Investor Presentation
July 2022
Exscientia
Investor Day
January 2024
MindMed
Investor Presentation
April 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights